Travere Therapeutics Valuation
| TVTX Stock | USD 18.81 0.11 0.59% |
At this time, the company appears to be fairly valued. Travere Therapeutics has a current Real Value of $19.2 per share. The regular price of the company is $18.81. Our model measures the value of Travere Therapeutics from inspecting the company fundamentals such as Shares Outstanding of 87.03 M, operating margin of (0.89) %, and Return On Equity of -2.8 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Travere Therapeutics' valuation include:
Price Book 76.1026 | Enterprise Value 1.8 B | Enterprise Value Ebitda (5.67) | Price Sales 8.0469 | Enterprise Value Revenue 8.6613 |
Fairly Valued
Today
Please note that Travere Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Travere Therapeutics is based on 3 months time horizon. Increasing Travere Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Travere Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Travere Stock. However, Travere Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 18.81 | Real 19.2 | Target 16.21 | Hype 19.28 | Naive 20.14 |
The intrinsic value of Travere Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Travere Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Travere Therapeutics helps investors to forecast how Travere stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Travere Therapeutics more accurately as focusing exclusively on Travere Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Travere Therapeutics' intrinsic value based on its ongoing forecasts of Travere Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Travere Therapeutics' closest peers.
Travere Therapeutics Cash |
|
Travere Valuation Trend
Analysing the historical paterns of Travere Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Travere Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Travere Revenue by Product
Travere Therapeutics Total Value Analysis
Travere Therapeutics is at this time anticipated to have valuation of 1.76 B with market capitalization of 1.64 B, debt of 404.78 M, and cash on hands of 553.17 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Travere Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.76 B | 1.64 B | 404.78 M | 553.17 M |
Travere Therapeutics Investor Information
About 99.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 4.52. Travere Therapeutics had not issued any dividends in recent years. The entity had 1:9 split on the 8th of November 2011. Based on the key indicators related to Travere Therapeutics' liquidity, profitability, solvency, and operating efficiency, Travere Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January.Travere Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Travere Therapeutics has an asset utilization ratio of 18.41 percent. This suggests that the Company is making $0.18 for each dollar of assets. An increasing asset utilization means that Travere Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Travere Therapeutics Ownership Allocation
Travere Therapeutics shows a total of 87.03 Million outstanding shares. The majority of Travere Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Travere Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Travere Therapeutics. Please pay attention to any change in the institutional holdings of Travere Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Travere Therapeutics Profitability Analysis
The company reported the previous year's revenue of 145.24 M. Net Loss for the year was (376.33 M) with loss before overhead, payroll, taxes, and interest of (31.35 M).About Travere Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Travere Therapeutics. We calculate exposure to Travere Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Travere Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 133.8 M | 163.4 M | |
| Pretax Profit Margin | (2.59) | (2.46) | |
| Operating Profit Margin | (2.59) | (2.46) | |
| Net Loss | (0.77) | (0.81) | |
| Gross Profit Margin | 0.92 | 1.07 |
Travere Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 74.3 M |
Travere Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Travere Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Travere we look at many different elements of the entity such as Travere's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Travere Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Travere Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Travere Therapeutics' worth.Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.